Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Photo of Kees Been
Individual Investor

Kees Been

Overview

Edit Overview Section
Number of Founded Organizations 1
CB Rank (Investor) 193,084
Kees Been is the Chief Executive Officer at BIAL Biotech Investments, Inc. Kees Been attended INSEAD.

Jobs

Edit Jobs Section
Number of Current Jobs 1
Number of Past Jobs 3
Kees Been is the CEO at BIAL Biotech. Additionally, Kees Been has had 3 past jobs including Founder, President & Chief Executive Officer at Lysosomal Therapeutics.
Organization Name  
Title At Company  
Start Date  
End Date  
Lysosomal Therapeutics Logo
Lysosomal Therapeutics
Founder, President & Chief Executive OfficerJul 2013Aug 2020
EnVivo Pharmaceuticals Logo
EnVivo Pharmaceuticals
President & CEO2005Feb 2013
Biogen Logo
Biogen
Senior Vice President, Oncology Business Unit20022003

Related Hubs

Edit Related Hubs Section
Hub Name  
CB Rank (Hub)  
East Coast Therapeutics Companies Logo
East Coast Therapeutics Companies
11,949
New England Therapeutics Companies Logo
New England Therapeutics Companies
26,059
Greater Boston Area Therapeutics Companies Logo
Greater Boston Area Therapeutics Companies
35,207
Massachusetts Biotechnology Companies Logo
Massachusetts Biotechnology Companies
23,529
Massachusetts Therapeutics Companies Logo
Massachusetts Therapeutics Companies
36,737
Northeastern US Therapeutics Companies Logo
Northeastern US Therapeutics Companies
15,609
Greater Boston Area Biotechnology Companies Logo
Greater Boston Area Biotechnology Companies
23,988

Education

Edit Education Section
Kees Been studied at Wageningen University and Research and  INSEAD.

Events

Edit Events Section
Number of Events 1
Kees Been has participated in 1 event, IoT Blockchain Summit Atlanta 2018 on Oct 29, 2018.

Recent News and Activity

Edit Recent News and Activity Section
Number of News Articles 10
News•Jun 27, 2016
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jan 6, 2016
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Dec 21, 2015
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Dec 21, 2015
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Feb 3, 2015
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 12, 2014
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 12, 2014
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jul 11, 2013
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Dec 9, 2008
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Oct 31, 2008
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
View All
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(b82cf0e 1)
|